Last reviewed · How we verify

NCT06122597

A Clinical Trial to Evaluate the Efficacy of ConcenTrace to Buffer pH Levels Within the Body.

Completed NA Last updated 23 August 2024
What this trial tests

NA trial testing ConcenTrace in pH in 40 participants. Completed in 31 January 2024.

Timeline
5 October 2023
Primary endpoint
31 January 2024
31 January 2024

Quick facts

Lead sponsorTrace Minerals
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment40
Start date5 October 2023
Primary completion31 January 2024
Estimated completion31 January 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Trace Minerals

Who can join

18 and older, any sex, with pH. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This virtual single-arm trial will last 12 weeks. Participants will take the drops daily and complete questionnaires at Baseline, Week 4, Week 8, and Week 12. Urine pH measurements will be taken at Baseline, Week 4, Week 8, and Week 12 using pH test strips.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ConcenTrace

Trials testing the same drug.

Other Trace Minerals trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06122597.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing